Mylan saw profits tumble in the second quarter on revenue that skidded 5 percent as the local drug giant cut production at its flagship manufacturing plant in Morgantown, W.Va., and announced its board was exploring strategic alternatives because it believes its shares are undervalued.
Net income was $37.5 million, or 7 cents per share, down 87 percent from $297 million, or 55 cents per share, in the same quarter last year.
Excluding special items, adjusted earnings fell 3 percent to $1.07 per share from $1.10 per share, well below the consensus estimate on Wall Street of $1.22 per share.
Revenue was $2.81 billion, down from $2.96 billion, which reflects a 22 percent decline in sales in North America where the company has been hurt by lower sales volume, including declining sales of the EpiPen emergency allergy shot.
U.S. sales also were knocked back by a previously announced restructuring at the Morgantown plant, where the company has laid off workers, cut production levels and discontinued a number of products “aimed at reducing complexity at the facility,” Mylan said.
The restructuring came on the heels of a U.S. Food and Drug Administration inspection that found a number of problems at the plant.
Read More
“The fundamentals of Mylan’s global business remain strong,” CEO Heather Bresch said in a statement releasing the second-quarter results.
The company slashed its 2018 per-share earnings guidance to a range of $4.55 to $4.90, down from $5.20 to $5.60. Revenue guidance also was lowered to a range of $11.25 billion to $12.25 billion, down from $11.75 billion to $13.25 billion.
In a separate statement, Mylan’s board said it has formed a strategic review committee to evaluate “a wide range of alternatives to unlock the true value” of the company.
“The board has not set a timetable for its evaluation of alternatives and there can be no assurance that any alternatives will be implemented,” the statement said.
Ms. Bresch told analysts in a conference call that it was too early to discuss specifics because the review process had just begun. “There are no things not on the table,” she said.
Some possibilities could include a sale or merger, spinning off one or more businesses, or taking the company private.
Also on the call, Mylan President Rajiv Malik said consumers should continue to expect supply problems with the EpiPen, which is produced for Mylan by Pfizer.
“Pfizer continues to experience interruptions in production of EpiPen,” he said. “Supplies will continue to vary from pharmacy to pharmacy and may not always be available.”
In a filing with the Securities and Exchange Commission late Wednesday, Mylan said that a restructuring program announced in December 2016 would continue through fiscal 2018, at a cost ranging between $500 million and $600 million, up from a prior estimate of $375 million to $450 million. The company also expects to incur additional costs related to the program that can’t be reasonably estimated, the filing said.
After falling earlier in the day, Mylan shares added 69 cents, or 1.79 percent, to close at $39.23 Wednesday.
Mylan stock price history, Jan. 2, 2015 - Aug. 8, 2018
Created with Highstock 6.1.1CloseJan '15Jul '15Jan '16Jul '16Jan '17Jul '17Jan '18Jul '18$20$30$40$50$60$70$80
*April 21, 2015, Teva Pharmaceutical Industries offered to buy Mylan for $82 a share. Mylan's closing stock price was $74.07. Source: Yahoo Finance | Post-Gazette
Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.
This story was updated at 5:45 p.m., Aug. 8, 2018.



Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.